I-Corps: Rapid, Low Cost Point-of-Care Microfluidic Cancer Screening Device

I-Corps：快速、低成本的护理点微流控癌症筛查设备

• 批准号: 2224974
• 负责人: Max Roman
• 金额: $ 5万
• 依托单位: New Jersey Institute of Technology
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-01 至 2024-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2224974&HistoricalAwards=false
• 关键词: Corps; Rapid; Low; Cost; Point

The broader impact/commercial potential of this I-Corps project is the development of a biopsy screening method that enables early detection of cancer. Cancer cells can often grow and form tumors for nearly ten years before they are initially detected. This project focuses on producing a minimally invasive and cost-effective, point of care device for early cancer screening. This device is intended to help detect specific cancers earlier, thereby improving patient outcomes globally. If successful, the product is expected to have major economic impacts as a result of reducing healthcare expenditures for cancer treatment and improving the health of the workforce.This I-Corps project is based on the development of a point of care blood biopsy device for early screening and detection of cancer. The technology consists of two primary components: (1) a disposable microfluidics platform, and (2) an electronics and hardware enclosure. The microfluidic platform fractionates a tiny whole blood sample drawn from the patient and processes a targeted, enzyme-linked immunosorbent assay. The assay produces a chemiluminescent signal in response to the presence of circulating tumor cells that have epithelial cell adhesion molecule expression of 80% (i.e. breast, prostate, bladder, or pancreatic cancer). The disposable microfluidic platform is loaded into a table-top sized enclosure that houses the electronics and hardware used to autonomously control fluid handling (sorting, mixing, flushing, sensing) of the blood sample in a preprogrammed sequence. A photosensor contained in the enclosure detects the chemiluminescent signal produced by the assay. By reducing the time and skill typically required by medical personnel, patient outcomes can be improved and the cost of screening can be significantly reduced The size, cost, and ease of use of the device is well suited for point-of-care diagnostics in a clinical setting.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛的影响/商业潜力是开发一种活检筛查方法，该方法可以尽早发现癌症。 癌细胞通常可以生长并形成近十年的肿瘤，然后才被检测到。该项目着重于生产一种微创且具有成本效益的护理手段，用于早期癌症筛查。该设备旨在帮助较早地检测特定的癌症，从而改善全球患者的结果。如果成功的话，预计该产品将由于减少癌症治疗的医疗保健支出并改善劳动力的健康而产生重大的经济影响。此I-Corps项目基于开发用于早期筛查和发现癌症的护理血液活检装置。该技术由两个主要组成部分组成：（1）一次性微流体平台，以及（2）电子和硬件外壳。微流体平台分馏从患者中抽取的细小血液样本并处理针对性的，酶联的免疫吸附测定法。 该测定法对循环肿瘤细胞的存在产生化学发光信号，这些肿瘤细胞的上皮细胞粘附分子的表达为80％（即乳腺，前列腺，膀胱或胰腺癌）。一次性微流体平台被加载到一个台式尺寸的外壳中，该机箱容纳用于自主控制流体处理（排序，混合，冲洗，感应）的电子和硬件，以预编程的序列进行。围栏中包含的光发射器检测到该测定法产生的化学发光信号。通过减少医务人员通常需要的时间和技能，可以改善患者的预后，并且可以大大降低筛查成本的大小，成本和设备的易用性，非常适合在临床环境中进行临床诊断。本奖项奖可以反映NSF的法定任务，并通过评估基金会的范围来反映支持者的支持者，并通过基金会的范围进行了评估。